Log in
FREE 15-Day Trial
Intelligent Investor
Intelligent Investor
  1. Home
  2. Research & Advice
  3. Research Tools
  4. Shares
  5. Neuren Pharmaceuticals Limited (NEU)
  6. Company Announcements

Neuren Pharmaceuticals Limited (ASX: NEU) - Announcements

- Current share price for NEU : $20.710

ASX company news and announcements for Neuren Pharmaceuticals Limited (NEU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neuren Pharmaceuticals Limited (NEU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neuren Pharmaceuticals Limited (NEU), please use our Company Announcements tool to search across all ASX-listed companies.

Intelligent Investor free trial for buy hold sell stock recommendations

Latest company announcements for Neuren Pharmaceuticals Limited (NEU)

Search all Announcements
Market Cap ($m) Headline Announcement date/time + Price at ann'ment + Current price + Price
7D Avg		 Gain/Loss
$2,645 Neuren presenting at Jefferies Global Healthcare Conference 5 Jun 2023 4:32PM $12.670 $20.710 $21.800 risen by 63.46%
$2,645 Results of Meeting 30 May 2023 4:36PM $13.700 $20.710 $21.800 risen by 51.17%
$2,645 AGM Chair Address & CEO Presentation 30 May 2023 1:46PM $13.600 $20.710 $21.800 risen by 52.28%
$2,645 Notice of Annual General Meeting/Proxy Form 28 Apr 2023 9:30AM $14.300 $20.710 $21.800 risen by 44.83%
$2,645 Virtual AGM online guide 28 Apr 2023 9:29AM $14.300 $20.710 $21.800 risen by 44.83%
$2,645 Q1 2023 quarterly activity and cash flow report 28 Apr 2023 9:24AM $14.300 $20.710 $21.800 risen by 44.83%
$2,645 Appendix 4G 27 Apr 2023 9:23AM $14.280 $20.710 $21.800 risen by 45.03%
$2,645 2022 Annual Report to shareholders 27 Apr 2023 9:21AM $14.280 $20.710 $21.800 risen by 45.03%
$2,645 DAYBUE (trofinetide) launched in US - Neuren earns US$40m 18 Apr 2023 9:50AM $13.450 $20.710 $21.800 risen by 53.98%
$2,645 Application for quotation of securities - NEU 27 Mar 2023 1:27PM $13.210 $20.710 $21.800 risen by 56.78%
$2,645 Investor Presentation, 14 March 2023 14 Mar 2023 8:34AM $9.090 $20.710 $21.800 risen by 127.83%
$2,645 Notification of investor webinar 13 Mar 2023 2:30PM $9.170 $20.710 $21.800 risen by 125.85%
$2,645 FDA approves Daybue - the first treatment for Rett syndrome 13 Mar 2023 9:10AM $7.670 $20.710 $21.800 risen by 170.01%
$2,645 Initial Director's Interest Notice 2 Mar 2023 9:30AM $7.500 $20.710 $21.800 risen by 176.13%
$2,645 Neuren appoints Joe Basile to board of directors 2 Mar 2023 9:27AM $7.500 $20.710 $21.800 risen by 176.13%
$2,645 Investor presentation, 1 March 2023 1 Mar 2023 1:17PM $7.340 $20.710 $21.800 risen by 182.15%
$2,645 Investor Presentation, 24 February 2023 24 Feb 2023 3:30PM $7.175 $20.710 $21.800 risen by 188.64%
$2,645 Neuren reports 2022 full-year results 24 Feb 2023 9:36AM $7.130 $20.710 $21.800 risen by 190.46%
$2,645 Appendix 4E and 2022 full year accounts 24 Feb 2023 9:32AM $7.130 $20.710 $21.800 risen by 190.46%
$2,645 Application for quotation of securities - NEU 21 Feb 2023 4:22PM $7.160 $20.710 $21.800 risen by 189.25%
$2,645 Q4 2022 quarterly activity and cash flow report 31 Jan 2023 9:49AM $7.790 $20.710 $21.800 risen by 165.85%
$2,645 Prader-Willi syndrome IND for NNZ-2591 approved by FDA 23 Jan 2023 9:31AM $8.810 $20.710 $21.800 risen by 135.07%
$2,645 Neuren submits IND & first patients complete Phase 2 trials 23 Dec 2022 9:44AM $7.800 $20.710 $21.800 risen by 165.51%
$2,645 Becoming a substantial holder 7 Dec 2022 10:23AM $7.150 $20.710 $21.800 risen by 189.65%
$2,645 Ceasing to be a substantial holder 2 Dec 2022 7:30AM $7.710 $20.710 $21.800 risen by 168.61%

51 - 75 of 598 results

Page 3 of 24

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.